Blueprint Medicines (NASDAQ:BPMC) had its price objective boosted by equities research analysts at Goldman Sachs Group from $82.00 to $99.00 in a research report issued on Monday, The Fly reports. The firm presently has a “buy” rating on the biotechnology company’s stock. Goldman Sachs Group’s price target would suggest a potential upside of 37.77% from the company’s current price.

BPMC has been the subject of several other reports. Zacks Investment Research downgraded Blueprint Medicines from a “hold” rating to a “sell” rating in a research note on Thursday, November 2nd. Canaccord Genuity reiterated a “buy” rating and set a $56.00 target price on shares of Blueprint Medicines in a research report on Monday, September 11th. Wedbush reiterated an “outperform” rating and set a $82.00 target price (up from $70.00) on shares of Blueprint Medicines in a research report on Monday, November 6th. DA Davidson began coverage on Blueprint Medicines in a research report on Friday, September 29th. They set a “buy” rating and a $90.00 target price for the company. Finally, BidaskClub downgraded Blueprint Medicines from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 19th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and ten have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $83.78.

Blueprint Medicines (NASDAQ BPMC) traded up $0.30 during mid-day trading on Monday, reaching $71.86. The company’s stock had a trading volume of 296,800 shares, compared to its average volume of 427,879. Blueprint Medicines has a 1-year low of $25.34 and a 1-year high of $77.91. The company has a quick ratio of 11.28, a current ratio of 11.28 and a debt-to-equity ratio of 0.02.

Blueprint Medicines (NASDAQ:BPMC) last posted its quarterly earnings results on Tuesday, October 31st. The biotechnology company reported ($0.96) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.90) by ($0.06). Blueprint Medicines had a negative return on equity of 43.11% and a negative net margin of 437.83%. The business had revenue of $8.07 million during the quarter, compared to the consensus estimate of $5.35 million. During the same quarter in the previous year, the company earned ($0.62) earnings per share. The company’s revenue for the quarter was up 31.0% compared to the same quarter last year. sell-side analysts expect that Blueprint Medicines will post -3.76 EPS for the current fiscal year.

In other news, insider Anthony L. Boral sold 5,000 shares of the stock in a transaction that occurred on Monday, November 6th. The stock was sold at an average price of $70.40, for a total transaction of $352,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Marion Dorsch sold 18,334 shares of the stock in a transaction that occurred on Tuesday, November 21st. The shares were sold at an average price of $65.45, for a total value of $1,199,960.30. Following the transaction, the insider now owns 18,334 shares of the company’s stock, valued at $1,199,960.30. The disclosure for this sale can be found here. Insiders have sold a total of 72,639 shares of company stock valued at $4,871,743 over the last quarter. Corporate insiders own 3.40% of the company’s stock.

A number of large investors have recently added to or reduced their stakes in BPMC. Teachers Advisors LLC raised its holdings in Blueprint Medicines by 25.5% during the 1st quarter. Teachers Advisors LLC now owns 41,322 shares of the biotechnology company’s stock valued at $1,652,000 after buying an additional 8,390 shares during the period. Renaissance Technologies LLC raised its holdings in Blueprint Medicines by 256.2% during the 1st quarter. Renaissance Technologies LLC now owns 37,400 shares of the biotechnology company’s stock valued at $1,496,000 after buying an additional 26,900 shares during the period. Bank of America Corp DE raised its holdings in Blueprint Medicines by 105.0% during the 1st quarter. Bank of America Corp DE now owns 8,090 shares of the biotechnology company’s stock valued at $324,000 after buying an additional 4,144 shares during the period. Russell Investments Group Ltd. raised its holdings in Blueprint Medicines by 216.7% during the 2nd quarter. Russell Investments Group Ltd. now owns 33,452 shares of the biotechnology company’s stock valued at $1,695,000 after buying an additional 22,890 shares during the period. Finally, Strs Ohio raised its holdings in Blueprint Medicines by 12.8% during the 2nd quarter. Strs Ohio now owns 22,900 shares of the biotechnology company’s stock valued at $1,160,000 after buying an additional 2,600 shares during the period. Institutional investors own 91.40% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This story was first published by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://www.americanbankingnews.com/2017/12/11/goldman-sachs-group-boosts-blueprint-medicines-bpmc-price-target-to-99-00.html.

About Blueprint Medicines

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease.

The Fly

Analyst Recommendations for Blueprint Medicines (NASDAQ:BPMC)

Receive News & Ratings for Blueprint Medicines Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines Corporation and related companies with MarketBeat.com's FREE daily email newsletter.